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Platelet-derived Growth Factor Selectively Inhibits
NR2B-containing N-Methyl-D-aspartate Receptors in CA1
Hippocampal Neurons*□
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Michael A. Beazely‡, Aeni Lim‡, Hongbin Li‡, Catherine Trepanier§, XuanMao Chen‡, Bikram Sidhu‡,
and John F. MacDonald‡§1
From the Departments of ‡Physiology and §Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
Platelet-derived growth factor (PDGF) ␤ receptor activation
inhibits N-methyl-D-aspartate (NMDA)-evoked currents in hippocampal and cortical neurons via the activation of phospholipase C␥, PKC, the release of intracellular calcium, and a rearrangement of the actin cytoskeleton. In the hippocampus, the
majority of NMDA receptors are heteromeric; most are composed of 2 NR1 subunits and 2 NR2A or 2 NR2B subunits. Using
NR2B- and NR2A-specific antagonists, we demonstrate that
PDGF-BB treatment preferentially inhibits NR2B-containing
NMDA receptor currents in CA1 hippocampal neurons and
enhances long-term depression in an NR2B subunit-dependent
manner. Furthermore, treatment of hippocampal slices or cultures with PDGF-BB decreases the surface localization of NR2B
but not of NR2A subunits. PDGF␤ receptors colocalize to a
higher degree with NR2B subunits than with NR2A subunits.
After neuronal injury, PDGF␤ receptors and PDGF-BB are upregulated and PDGF␤ receptor activation is neuroprotective
against glutamate-induced neuronal damage in cultured neurons. We demonstrate that the neuroprotective effects of
PDGF-BB are occluded by the NR2B antagonist, Ro25-6981,
and that PDGF-BB promotes NMDA signaling to CREB and
ERK1/2. We conclude that PDGF␤R signaling, by preferentially
targeting NR2B receptors, provides an important mechanism
for neuroprotection by growth factors in the central nervous
system.

N-Methyl-D-aspartate (NMDA)2 receptors are tetrameric,
non-selective cation channels composed of two obligate NR1
and two variably expressed NR2 subunits (NR2A-D) although
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trimeric receptors (2NR1/NR2A/NR2B) are also likely to be
present (1). In the hippocampus, NR2A and NR2B are the dominant NR2 forms (2, 3). The majority of synaptic receptors
appear to contain the NR2A subunit, whereas NR2B-containing receptors are in greater density extrasynaptically (2, 4, 5),
however, this paradigm has recently been challenged (6). Extrasynaptic NMDA receptors or, alternatively, the NR2B-containing NMDA receptors have been directly implicated in the Ca2⫹
influx that causes excitotoxic cell death (7–10), whereas the
synaptic, NR2A-containing receptors have paradoxically been
linked to neuroprotection in ischemia (11, 12).
Platelet-derived growth factor (PDGF) receptors are highly
expressed in CA1 hippocampal neurons and are developmentally important but their functions in the mature CNS are
largely unknown (13). There are two major PDGF receptor isoforms (PDGF␣ and PDGF␤ receptors) found in the hippocampus (14). The most intense staining for PDGF␤ receptors is
found in the pyramidal cells of the hippocampus (15), whereas
PDGF␣ receptors are located primarily on glial cells in this
region (16). We have previously demonstrated that the PDGF␤
receptor ligand PDGF-BB inhibits synaptic NMDA receptors at
CA1 synapses (17) as well as NMDA-evoked currents of neurons acutely isolated from the CA1 region of the hippocampus
(17, 18) or from the prefrontal cortex (19).
PDGF␤ receptors have been implicated in neuroprotection
following ischemic events (20). For example, focal ischemia in
rat brain causes a rapid increase in PDGF-B chain isoform
mRNA transcripts that peaks at 24 h (21, 22). Furthermore,
PDGF␤ receptor expression rises rapidly after ischemia in rat
brain (22) and 24-h applications of PDGF-BB is neuroprotective against glutamate- or NMDA-induced death of cultured
hippocampal neurons (23). These results lead us to hypothesize
that PDGF␤ receptor-mediated neuroprotection involves the
inhibition of NMDA receptor signaling, specifically the inhibition of NR2B-containing NMDA receptors that are associated
with glutamate-induced toxicity.
We demonstrate that PDGF-BB preferentially inhibits
NR2B- and not NR2A-containing subtypes of NMDA receptors. In addition, treatment of hippocampal neurons with
PDGF-BB selectively decreases the surface expression of NR2B
subunits and their phosphorylation level. Furthermore, we
found that PDGF␤ receptors are predominantly localized
extrasynaptically and they colocalize with NR2B subunits.
PDGF-BB application also altered the ability of NMDA to signal
to transcription factors in hippocampal neurons. This work
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illustrates that the neuroprotective effects of PDGF-BB treatment of hippocampal neurons are due at least in part to a preferential decrease in the activity of NR2B-containing NMDA
receptors.

EXPERIMENTAL PROCEDURES
Reagents and Antibodies—PDGF-BB was purchased from
R&D Systems (Minneapolis, MN). Ro25-6981 was purchased
from Tocris Bioscience (Bristol, UK). NVPAAM077 was a generous gift from Novartis (Basel, Switzerland). NMDA, glycine,
kainate, and all other chemical reagents were purchased from
Sigma. Antibodies used include those raised against PSD-95
(Abcam, Cambridge, MA), PDGF␤ receptor (Epitomics, CA),
phosphotyrosine 1021 PDGF␤ receptor (Santa Cruz, Santa
Cruz, CA), phospho-ERK1/2 and ERK1/2 (Cell Signaling, Danvers, MA), NR1, NR2B, and NR2A antibodies from Chemicon
(Temecula, CA) were used for biotinylation and Western blotting, and NR2A (Covance, Berkeley, CA) and NR2B antibodies
(Zymed Laboratories Inc., San Francisco, CA) were used for
immunocytochemistry. Anti-␣-actinin was purchased from
Sigma. For immunoprecipitation and phosphorylation experiments, anti-phosphotyrosine 1472 (Biomol), anti-NR2B (Santa
Cruz), anti-phosphotyrosine (Santa Cruz), anti-NR1 phosphoserine 896 and 897, and anti-NR1 (Upstate) antibodies were
employed as well as anti-PDGF␤ receptor antibodies precoupled to agarose beads (Santa Cruz). All secondary antibodies including Alexa 488, Alexa 568, and streptavidin-conjugated
Alexa 568 were obtained from Molecular Probes (Eugene, OR).
Cell Isolation and Whole Cell Recording—CA1 neurons were
isolated from hippocampal slices of postnatal day 14 –21 Wistar
rats as previously described (24). The extracellular solution was
composed of 140 mM NaCl, 1.3 mM CaCl2, 25 mM HEPES, 33
mM glucose, 5.4 mM KCl, 0.5 M tetrodotoxin, and 0.5 M glycine, with pH 7.3–7.4 and osmolarity ranging from 320 to 330
mosmol. Recordings were done at room temperature. The
membrane potential was held at ⫺60 mV throughout the
recordings and a voltage step of 10 mV was applied prior to
NMDA application to monitor series resistance. The intracellular solution consisted of 11 mM EGTA as intracellular calcium
chelating buffer, 10 mM HEPES, 2 mM MgCl2, 2 mM tetraethylammonium chloride to block K⫹ channel, 1 mM CaCl2, 140 mM
cesium fluoride, and 4 mM K2ATP. NMDA currents were
evoked by rapid application of NMDA solution delivered from
a multibarreled fast perfusion system for 3 s every minute. The
solution was delivered at a rate of ⬃1 ml/min.
Hippocampal Slice Recording—Hippocampal slices were
prepared from 3- to 4-week-old male Wistar rats and placed in
a holding chamber for at least 1 h prior to recording. A single
slice was transferred to a recording chamber and superfused
with artificial cerebral spinal fluid (5 ml/min) composed of (in
mM) 120 NaCl, 4 KCl, 1.25 NaH2PO4, 1.3 MgCl2, 2.6 CaCl2, 26
NaHCO3, 10 D-glucose, saturated with 95% O2, 5% CO2 at room
temperature. Synaptic responses were evoked with bipolar
tungsten electrodes located about 50 m from the cell body
layer in CA1. Field potential recordings were made with glass
micropipettes filled with artificial cerebral spinal fluid placed in
the stratum radiatum 60 – 80 m from the cell body layer. Test
stimuli were evoked at 0.033 Hz with the stimulus intensity set
MARCH 20, 2009 • VOLUME 284 • NUMBER 12

to 70% of that which produced maximum synaptic responses.
Long-term depression was induced by a 1-Hz, 15-min low-frequency stimulation delivered through the stimulation electrode. The value of fEPSP amplitude from the 10-min period
immediately before tetanus was defined as baseline (100%). The
magnitude of LTD was determined by averaging the amplitude
of fEPSPs collected 50 – 60 min after the low-frequency stimulation. Data were recorded with an Axoclamp 2B amplifier and
sampled at 10 kHz by computer. Statistical significance of data
were determined using Student’s t test or analysis of variance
with a level of significance, p ⬍ 0.05.
Surface Biotinylation Assay—The CA1 region of the hippocampus was microdissected from day 14 –22 Wistar rat pups.
CA1 slices (5–10 per condition) were incubated for 10 min with
control or PDGF-BB. Slices were washed in ice-cold ECF and
incubated with 0.5 mg/ml Sulfo-NHS-LC-biotin (Pierce) for 30
min. The biotin reaction was quenched by washing with 10 mM
glycine. Slices were washed twice more and homogenized in
solubilization buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 30 mM sodium pyrophosphate, 1 mM
␤-glycerophosphate, 1% Triton, 1 mM Na3VO4, and MINI mixture (Roche) supplemented with 1% SDS. Total protein concentration was determined by BCA Protein Assay (Pierce). Lysate
protein concentrations were normalized and lysates were incubated with streptavidin beads overnight at 4 °C (Sigma). Beads
were washed three times in lysis buffer and boiled in loading
buffer for 5 min before separation by SDS-PAGE. A similar
protocol was followed to examine the cell surface expression of
NR2B and PDGF␤ receptors in cultured hippocampal neurons
(15–23 days in vitro) except the 10-min drug treatment was at
37 °C.
Immunoprecipitation—CA1 slices were homogenized in
immunoprecipitation buffer (20 mM Tris, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 30 mM Na pyrophosphate, 1 mM
␤-glycerophosphate, 1% Nonidet P-40, 1 mM Na3VO4, and
MINI mixture). Lysate protein concentrations were normalized
after protein determination and 1 mg of total protein was incubated overnight with anti-PDGF␤ receptor conjugated to agarose beads. Beads were washed and boiled in loading buffer
prior to SDS-PAGE. For NR2B or NR2A immunoprecipitation,
crude membrane fractions were obtained by centrifugation at
14,000 ⫻ g for 20 min, followed by solubilization of the pellet in
1% SDS buffer, and 5-fold dilution with 1% Triton buffer.
Western Blot and Analysis—For transcription factor blots,
hippocampal cultures were lysed in loading buffer and samples
were directly loaded onto gels. Homogenates were subjected to
SDS-PAGE using 10 or 7.5% gels. Proteins were transferred to
nitrocellulose membranes, blocked with 5% nonfat dry milk in
Tris-buffered saline for 1 h at room temperature or overnight at
4 °C, and incubated in primary antibodies for 1 h or overnight at
4 °C. Membranes were washed three times in Tris-buffered
saline with 0.1% Tween 20, incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h, washed again,
and bound antibodies were visualized by the enhanced chemiluminescence method. Densitometric analysis of Western blots
was performed using the Kodak Image Station 2000R software.
Immunocytochemistry—Day 14 –21 hippocampal-cultured
neurons were washed with PBS twice, then fixed in 4%
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 1. A, vehicle (0.0002% bovine serum albumin, 8 M HCl) or 10 ng/ml PDGF-BB was applied to
isolated CA1 hippocampal neurons (as indicated by the black bar). NMDA-evoked currents were recorded
every 60 s by application of 1 M NMDA, 0.5 M glycine for 3 s. Sample traces from the same cell are shown
with vehicle application (black trace) or with 10 ng/ml PDGF-BB application (gray trace). Data are representative of six experiments. B, NMDA-evoked currents were recorded every 60 s by application of 1 M
NMDA, 0.5 M glycine for 3 s. Vehicle or PDGF-BB was applied to isolated CA1 hippocampal neurons in the
presence of 500 nM Ro25-6981 (NR2B-selective antagonist). Sample traces from the same cell are shown
with vehicle application (black trace) or with 10 ng/ml PDGF-BB application (gray trace). Data are representative of six experiments. C, NMDA-evoked currents were recorded every 60 s by application of 1 M
NMDA, 0.5 M glycine for 3 s. Vehicle or PDGF-BB was applied to isolated CA1 hippocampal neurons in the
presence of 50 nM NVP-AAM077 (NR2A-selective antagonist). Sample traces from the same cell are shown
with vehicle application (black trace) or with 10 ng/ml PDGF-BB application (gray trace). Data are representative of seven experiments.

8056 JOURNAL OF BIOLOGICAL CHEMISTRY

paraformaldehyde and 4% sucrose
in phosphate-buffered saline (PBS)
for 20 min. The cultures were rinsed
in PBS and permeabilized in 0.25%
Triton X-100 in PBS (PBST) for 30
min. The cultures were incubated
with PBS blocking buffer containing
10% normal goat serum and then
incubated in the first primary antibody for 48 h at 4 °C. The coverslips
were washed in three times PBST
incubated with secondary antibody:
Alexa 488 or Alexa 568 (Molecular
Probes, 1:1000) for 1 h in PBS with
1% normal goat serum. Coverslips
were washed again and subsequently incubated with the second
primary antibody. After washing
and incubation with a second secondary antibody, the coverslips
were mounted with Prolong Gold
antifade solution (Invitrogen). Fluorescent images were visualized on
Leica TCS SL confocal microscope
with a ⫻63 oil-based objective.
Image Analysis—A quantitative
analysis was performed to compare
the level of colocalization between
NR2A containing NMDA receptors
and NR2B containing NMDA
receptors with respect to PDGF␤
receptor or between PDGF␤ receptor and PSD-95. A total of three sets
of coverslips were used per condition, five neurons were imaged from
each coverslip, and nine images
from processes were analyzed. Thus
at least 180 images were evaluated
per condition. Background signaling was subtracted from each image
and percentage of colocalization
was calculated using a modified
intensity correlation analysis with
ImageJ (24).
Total
Versus
Extrasynaptic
NMDA Receptor Activation—To
differentiate between activation of
the entire pool of NMDA receptors
and the extrasynaptic pool, we used
a protocol initially developed by
Hardingham’s group (7, 25). Briefly,
for total NMDA receptor activation,
cells were incubated for 3 min with
100 M NMDA, 10 M glycine, 1 M
tetrodotoxin, 40 M 6-cyano-7-nitroquinoxaline-2,3-dione, and 5 M
nifedipine after pretreatment with
vehicle or 10 ng/ml PDGF-BB for 10
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min. To activate extrasynaptic NMDA receptors exclusively,
we added 50 M MK-801, 10 M bicuculline, 10 M glycine, and
5 M nifedipine during the last 2 min of the vehicle/PDGF-BB
pretreatment. After stimulation, cultures were lysed directly in
loading buffer, samples were resolved by SDS-PAGE, and incubated with antibodies as indicated above.
Cell Death Assay—We adapted the cell death assay protocol
from Carrier et al. (26). Briefly, 18 –21-day-old hippocampal
neurons on 12-well plates were pretreated for 10 min with
drugs, washed, and incubated with vehicle or NMDA/glycine
for 3 min. The cells were washed and returned to culture
medium overnight. After 24 h, cells were fixed in 4% paraformaldehyde in PBS, permeabilized with 0.4% Triton in PBS,
blocked for 30 min with 10% bovine serum albumin, and incubated with anti-MAP2 (1:5000, Sigma) overnight at 4 °C. The
following day, the cells were washed in 0.4% Triton/PBS three
times and incubated with anti-mouse horseradish peroxidase
antibody (Amplex Elisa Development Kit, Molecular Probes).
Cells were washed three times and incubated with Amplex
UltraRed substrate for 30 min. Absorption at 565 nM was measured and data were normalized to control samples.
Statistical Analysis—Statistical analysis of the data were
completed using the Prism GraphPad program. All population
data were expressed as mean ⫾ S.E. Significance level was set at
p ⬍ 0.05. Data for colocalization were analyzed by the MannWhitney test and Kruskal-Wallis non-parametric tests and data
for biotinylation and Western blots were analyzed by Student’s
t test or analysis of variance.
Animals—All animal experiments were performed in agreement with the guidelines of the policies on the Use of Animals at
the University of Toronto.

RESULTS
PDGF␤ receptors are activated by dimers of the isoform
PDGF-B and heterodimers of PDGF-B and PDGF-A (14).
Application of PDGF-BB to isolated or cultured hippocampal
neurons caused a long-lasting decrease in peak NMDA-evoked
currents (17, 18). To test if the inhibition of NMDA receptor
currents involved NR2B over NR2A receptors we applied NR2
subunit-selective antagonists to the bath (27, 28). In isolated
CA1 neurons, PDGF-BB application decreased peak NMDAevoked currents with a maximal inhibition occurring between 8
and 10 min after PDGF-BB treatment (Fig. 1A). However, in the
presence of the highly NR2B-selective antagonist, Ro25-6981
(27), PDGF-BB failed to alter NMDA-evoked currents (Fig. 1B).
In contrast, when NR2A-containing NMDA receptors were
inhibited with NVPAAM077 (28), PDGF-BB decreased peak
NMDA-evoked currents (Fig. 1C). NVPAAM077 is a competitive antagonist with limited selectivity between NR2A and
NR2B receptors so the concentration of NVPAAM077 was
chosen to reduce NR2A currents by about 80%, whereas
reducing NR2B only by about 10% (29). The percentage inhibition of both peak and steady-state currents in control cells,
in cells treated with NVPAAM077 or Ro25-6981, are presented in Table 1. Taken together these experiments suggest
that the inhibition of NMDA currents by PDGF-BB is largely
dependent on NR2B- and not NR2A-containing NMDA
receptors.
MARCH 20, 2009 • VOLUME 284 • NUMBER 12

TABLE 1
PDGF-BB inhibition of NMDA-evoked currents in isolated
hippocampal neurons in the presence of NR2A- or NR2B-specific
antagonists
The t ⫽ 14 min time point was chosen for the analysis. Data shown are mean ⫾ S.E.
of the mean of five to seven experiments.

a

Peak current

Steady-state current

NMDAR
antagonist

Vehicle

PDGF-BB

Vehicle

PDGF-BB

None
Ro25-6981
NVPAAM077

104 ⫾ 5%
98 ⫾ 2%
100 ⫾ 6%

79 ⫾ 5%a
99 ⫾ 5%
75 ⫾ 4%a

83 ⫾ 5%
74 ⫾ 6%
89 ⫾ 7%

65 ⫾ 13%
86 ⫾ 4%
71 ⫾ 16%

p ⬍ 0.01 compared to vehicle (Student’s t test).

In light of a report that PDGF receptors decreased ␣-amino3-hydroxy-5-methylisoxazole-4-proprionic acid receptor
(AMPAR)-mediated currents in neurons of the tractus solitarius, we examined if AMPARs were similarly reduced by
PDGF-BB in isolated CA1 pyramidal neurons (30). Kainate was
used to activate AMPA-mediated currents because this agonist
results in a much larger and consistent steady-state current (31,
32). We did not observe any effect of PDGF-BB application on
kainate-evoked currents although we observed some characteristic time-dependent decrease in the amplitude of these currents (33, 34) (supplemental Fig. S1).
We previously reported that PDGF-BB treatment of hippocampal slices does not significantly alter the surface expression of the NR1 subunit in neurons from the CA1 region of the
hippocampus or in cortical neurons (19). To investigate the
effects of PDGF-BB treatment on surface expression of NR2
subunits, we treated cultured hippocampal neurons and hippocampal slices with PDGF-BB (10 ng/ml) for 10 min. In hippocampal slices PDGF-BB treatment robustly decreased the
surface expression of the NR2B subunit but not the NR2A subunit of the NDMA receptor (Fig. 2, A and B). Surface expression
was also reduced for the PDGF␤ receptor (Fig. 2, A and B).
PDGF-BB treatment decreased surface NR2B expression to
35 ⫾ 12% of control, NR2A surface expression was unchanged
at 100 ⫾ 30%, and as previously reported in Beazely et al. (19),
NR1 surface expression decreased to 87 ⫾ 11%. The changes in
surface expression of NR2A and NR1 were not statistically different from control. As a control, we monitored the biotinylation of the intracellular protein ␣-actinin (Fig. 2A). Given the
slight, but not statistically significant, decrease in NR1, and the
variability in the changes of NR2A surface expression, it
remains unclear if a portion of the NR1 subunits are internalized with NR2B, or if NR2A replaces NR2B in cell surface
NMDA receptors. In cultured hippocampal neurons PDGF-BB
application also internalized the NR2B subunit and PDGF␤
receptors, but not NR2A (Fig. 2, C and D).
PDGF-BB treatment of hippocampal neurons inhibits
NMDA-evoked currents and reduces surface expression of
NR2B subunits. To investigate if endocytosis is the mechanism
whereby PDGF-BB inhibits NMDA currents we applied
PDGF-BB in the absence or presence of two peptides that
inhibit clathrin-mediated endocytosis. Neither the amphiphysin-SH3 peptide (35–37) nor the dynamin inhibitory peptide
(36) attenuated the inhibition of NMDA currents by PDGF-BB
(supplemental Fig. S2, A and B). To control for the ability of the
amphiphysin-SH3 peptide to attenuate internalization we
demonstrated a complete attenuation of D1 dopamine recepJOURNAL OF BIOLOGICAL CHEMISTRY
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tyrosine phosphorylation state of
NR2A or NR2B (81 ⫾ 22 and 117 ⫾
10% versus control, respectively),
nor any changes in the phosphorylation of serines 896 and 897 on the
NR1 subunit (107 ⫾ 16 and 110 ⫾
29% versus control, respectively).
Although PDGF␤ receptors are
expressed in hippocampal neurons
(15, 41) very little is known about
their localization. To investigate the
localization of PDGF␤ receptors in
hippocampal neurons, as well as
their potential colocalization with
NMDA receptors, we imaged
PDGF␤ receptors and NMDA
receptor subunits in 2–3-week-old
cultured hippocampal neurons.
When an antibody directed against
the synaptic marker PSD-95 was
compared with that recognizing
PDGF␤ receptor it was apparent
that PDGF␤ receptors did not show
a
strong synaptic localization (Fig.
FIGURE 2. PDGF-BB application results in the selective reduction of the surface expression of NR2B. CA1
hippocampal slices were treated with vehicle or 10 g/ml PDGF-BB for 10 min. The slices were biotinylated and 4A). PDGF␤ receptor localization
lysates were incubated overnight with streptavidin beads. A, total lysates or biotinylated samples were blotted using was subsequently compared with
antibodies against NR1 (n ⫽ 5), NR2B (n ⫽ 7), NR2A (n ⫽ 7, C), PDGF␤ receptor (n ⫽ 4), or ␣-actinin (n ⫽ 4). B, PDGF-BB
treatment decreases the surface localization of NR2B and PDGF␤ receptors, but not NR1 or NR2A (*, p ⬍ 0.05 versus NR2A and NR2B subunits. PDGF␤
vehicle, Student’s unpaired t tests). C and D, PDGF-BB treatment also decreased NR2B (n ⫽ 4) and PDGF␤ receptor receptors colocalized to a much
(n ⫽ 4) surface localization in hippocampal cultures (*, p ⬍ 0.05 versus vehicle, Student’s unpaired t tests).
higher degree with the NR2B versus
the NR2A subunit (Fig. 4, B and C).
Quantification using Manders’ overlap coefficient (42, 43)
demonstrated that the colocalization of PGDF␤ receptors with
NR2B was significantly greater than with either PSD-95 or
NR2A (Fig. 4D). To ensure that the differences in the Manders’
overlap coefficient analysis between PDGF␤ receptors localization with NR2A and NR2B was not due to differences in staining intensity, we counted the total number of pixels for PDGF␤
receptors (Fig. 4E) and NR2A and -2B (Fig. 4F). These images
FIGURE 3. Acutely dissected hippocampal slices were incubated for 10
min with vehicle (control, ⴚ) or PDGF-BB 10 ng/ml (ⴙ). Lysates were illustrate that PDGF␤ receptors are primarily extrasynaptic and
resolved on SDS gels, transferred to nitrocellulose membranes, and probed colocalize to a greater degree with NR2B compared with the
with antibodies directed against phosphorylated tyrosine 1472. Membranes NR2A subunit.
were stripped and reprobed for total NR2B (n ⫽ 4).
PDGF␤ receptors colocalize with NR2B subunits and both
are internalized after PDGF-BB treatment. To determine
tor-mediated increases in NMDA currents in isolated hip- whether PDGF␤ receptors and NR2B subunits share a physical
pocampal neurons (supplemental Fig. S2C). These results dem- interaction we treated hippocampal CA1 slices with vehicle or
onstrate that the inhibition of NMDA currents by PDGF-BB 10 ng/ml PDGF-BB. Lysates were subsequently incubated with
is not dependent on clathrin-dependent NMDA receptor anti-PDGF␤ receptor antibodies pre-conjugated to agarose
internalization.
beads. Although the agarose-PDGF␤ receptor antibodies
NMDA receptor trafficking, specifically the trafficking of the pulled down PDGF␤ receptors, Abl and Src kinases (data not
NR2B subunit, is highly dependent upon the phosphorylation shown), we did not detect NR2B in either of the immunopreof NR2B (38 – 40). We examined the total tyrosine phosphoryl- cipitated samples (supplemental Fig. S3). This result suggests
ation of the NR2B and NR2A subunits, as well as the site-spe- that although the PDGF␤ receptor and NR2B are colocalized
cific phosphorylation of tyrosine 1472 on the NR2B subunit, and both are internalized upon PDGF-BB treatment, they do
and serines 896 and 897 on the NR1 subunit after treatment of not appear to physically interact with each other.
hippocampal slices with PDGF-BB. PDGF-BB significantly
We previously reported that PDGF-BB depressed isolated
increased the phosphorylation of tyrosine 1472 on the NR2B NMDA receptor-mediated synaptic currents at CA3-CA1 synsubunit (191 ⫾ 17% of control, n ⫽ 5, p ⬍ 0.05, unpaired Stu- apses without altering the amplitude of LTP of CA1 EPSPs (17).
dent’s t test, Fig. 3). We did not observe any changes in the total The contribution of NR2A versus NR2B receptors to either LTP
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FIGURE 4. PDGF␤ receptors are primarily extrasynaptic and colocalize with NR2B. A, merged image of PDGF␤ receptor staining (green) and PSD-95
staining (red), including a high magnification image of one of the processes. Boxes represent regions of interest that were analyzed for Manders’ overlap
coefficient. The color scatter plot shows green, red, and yellow (overlap) pixels. The average Manders’ overlap coefficient was 0.400. B, merged image of PDGF␤
receptor staining (red) and NR2B staining (green), including a high magnification image of one of the processes. Boxes represent regions of interest that were
analyzed for Manders’ overlap coefficient. The color scatter plot shows green, red, and yellow (overlap) pixels. The average Manders’ overlap coefficient was
0.808. C, merged image of PDGF␤ receptor staining (red) and NR2A staining (green), including a high magnification image of one of the processes. Boxes
represent regions of interest that were analyzed for Manders’ overlap coefficient. The color scatter plot shows green, red, and yellow (overlap) pixels. The
average Manders’ overlap coefficient was 0.438. D, PDGF␤ receptors show significantly higher colocalization with NR2B compared with NR2A or PSD-95. *, p ⬍ 0.05.
Comparison of total pixel count between PDGF␤ receptor images and between NR2A and NR2B were not significantly different (data not shown). E and F, comparison
of total pixel count between PDGF␤ receptor images and between NR2A and NR2B, non-parametric statistical comparison. PDGF␤ receptor pixel numbers are not
significantly different (p ⬎ 0.05) and NR2A and NR2B pixel numbers are not significantly different (p ⬎ 0.05).

or LTD has proven to be highly controversial. It was suggested
that NR2B receptors play a more dominant role in LTD (44) but
a number of laboratories report that there is only a partial or no
subunit dependence to these forms of CA1 synaptic plasticity
(29, 45). Furthermore, there are several reports that the
NR2B antagonists, ifenprodil and Ro28-6981, enhance rather
than block LTD (45, 46). In the visual cortex it is the ratio of
expression of NR2A/NR2B receptors that determines the
direction of synaptic plasticity, LTD/LTP rather than the actual
participation of a given subtype of NMDAR (47). Our results
suggest that PDGF-BB selectively reduces the contribution of
NR2B receptors therefore we examined the effect of PDGF-BB
on LTD. We used a frequency (1 Hz) and amplitude near the
threshold that reliably induced LTD. Consistent with several
previous reports (45, 46) LTD was substantially enhanced by
treatment with Ro25-6981 (% depression at 90 to 100 min; control 13 ⫾ 1.9%; Ro25-6981, 37% ⫾ 2.3, p ⬍ 0.01, one-way analysis of variance). Applications of PDGF-BB similarly enhanced
MARCH 20, 2009 • VOLUME 284 • NUMBER 12

the degree of LTD induced by stimulation at 1 Hz frequency
(Fig. 5A). This increase in the amplitude of LTD was entirely
occluded when Ro25-6981 was included in the bathing solution
during the PDGF-BB application (Fig. 5B), confirming the
dependence of the action of PDGF-BB on the NR2B-containing
NMDA receptor subtype. We did not attempt to use
NVPAAM077 as we could not adequately ensure its precise
concentration at the receptors in the slice.
Several reports have suggested that excessive stimulation
of NR2B-containing NMDA receptors with a relatively
higher degree of extrasynaptic localization may mediate
neurotoxicity (7–10). Consistent with reports of the neuroprotective properties of PDGF-BB, we demonstrate that
PDGF-BB selectively inhibits NR2B-containing NMDA
receptors. However, previous reports used longer incubations of cells with PDGF-BB (1–24 h) (22) compared with the
rapid (10 min) effects of PDGF-BB on NMDA currents and
NR2B surface expression. To determine whether 10-min
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 5. PDGF-BB enhanced long-term depression in CA1 region of hippocampal slice. A, vehicle (0.0002% bovine serum albumin, 8 M HCl) or
PDGF-BB (10 ng/ml) was applied for 10 min after stable baseline recording as
indicated by the open bar. Long-term depression was evoked by low-frequency stimulation after the vehicle treatment but the magnitude of LTD was
increased after PDGF-BB treatment. B, PDGF-BB (10 ng/ml) or PDGF plus
Ro25-6981 (0.5 M) was applied for 10 min after stable baseline recording as
indicated by the open bar. Ro25-6981 treatment did not block LTD, but
PDGF-BB failed to facilitate LTD in the presence of Ro25-6981. Insets, representative traces recorded at the indicated time (numbers). Calibration bars,
vertical ⫽ 0.25 mV; horizontal ⫽ 5 ms.

involve signaling to CREB and MAPK (8, 10, 50 –52). PDGF␤
receptor activation enhances ERK1/2 phosphorylation in several systems via the recruitment of Grb2 scaffold proteins, via
phosphatidylinositol 3-kinase, via activation of G␣i, or after
being transactivated by G-protein coupled receptors such as
the D4 dopamine receptor (14, 53). To investigate the potential
of PDGF␤ receptors to alter NMDA signaling to ERK1/2 and
CREB, we incubated 14 –21-day-old cultured hippocampal
neurons with vehicle or PDGF-BB for 10 min, followed by stimulation of the total population of NMDA receptors or alternatively just the extrasynaptic population of NMDA receptors
(25, 53). In control hippocampal cultures, activation of all
NMDA receptors did not alter CREB phosphorylation, however, after PDGF-BB treatment, NMDA treatment robustly
enhanced phospho-CREB levels (Fig. 7, A and B). Conversely,
extrasynaptic NMDA receptor activation inhibited both CREB
and ERK phosphorylation, but not in cultures pretreated with
PDGF-BB (Fig. 7, D–F). These results suggest that PDGF-BB
treatment promotes NMDA signaling to ERK and CREB, perhaps by diminishing the contribution of NR2B-containing
NMDA receptors to the net response to NMDA.

DISCUSSION

FIGURE 6. PDGF-BB is neuroprotective. Day 18 –21 cultured hippocampal
neurons were pretreated for 10 min with vehicle (ECF), 10 ng/ml PDGF-BB, 2.5
M Ro25-6981, or both. Cells were subsequently incubated with vehicle (ECF)
or 100 M NMDA, 1 M glycine for 3 min. ECF was aspirated and cells were
returned to media for 24 h before determining cell viability as determined by
enzyme-linked immunosorbent assay. Data represent the mean ⫾ S.E. of four
experiments (*, p ⬍ 0.05, analysis of variance with Bonferroni’s post-test compared with NMDA-treated cells alone, second bar).

PDGF-BB treatment could protect cells against NMDA toxicity, we used a MAP2 immunoreactivity assay similar to that
used by Tseng and Dichter (23, 26, 48, 49). NMDA treatment
reduced MAP2 immunoreactivity (a measure of the remaining live neuronal cells) by half and a 10-min PDGF-BB pretreatment significantly attenuated this cell death (Fig. 6).
Pretreatment with Ro25-6981 also reduced the NMDA-induced cell death and occluded further protection by
PDGF-BB (Fig. 7), further suggesting a crucial role for the
NR2B-containing receptors in mediating the neuroprotective effects of PDGF-BB.
The differences between NR2B/extrasynaptic and NR2A/
synaptic NMDA receptors with regards to cell survival may
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Several growth factors important for neuronal development also play a role in NMDA receptor signaling and subunit trafficking in mature neurons. For example, receptor
tyrosine kinase receptors including TrkB and its ligand
brain-derived neurotropic factor have been extensively
implicated in the modulation of synaptic transmission and
plasticity (54 –56). Brain-derived neurotropic factor signaling has also been associated with NMDA-induced neuroprotection via preconditioning (57) and the induction of brainderived neurotropic factor gene expression is enhanced in
response to NR2B receptor activation (52). PDGF receptors,
which are also receptor tyrosine kinases critical for development of the central nervous system, have received much less
attention particularly with respect to their potential function
as regulators of synaptic transmission and cell survival (13).
The presence of PDGF-B isoform chains in neurons and
their processes was initially described by Sasahara et al. (58)
who hypothesized that PDGF-BB dimers might be released
following injury resulting in potential glial cell chemotaxis,
proliferation, and enhanced neuronal survival (59). However, PDGF-B is also located in axons and presumptive synaptic terminals presenting the possibility that it is released
during synaptic activity to serve as a modulator of synaptic
transmission, a concept that has received some substantial
support (13). In addition, staining PDGF␤ receptors the hippocampus is strong in pyramidal neurons (15). Therefore,
both the receptor and the ligand for PDGF␤ receptor signaling are associated with hippocampal synapses, supporting a
neuromodulatory role for this growth factor.
NR2B subunits predominate at extrasynaptic sites in hippocampal and other neurons. Both extrasynaptic NMDA
receptors and NR2B-containing NMDA receptors, regardless
of subcellular location, have been implicated in neuronal cell
death (11, 12, 60). Several lines of evidence have shown that
PDGF␤ receptor signaling is neuroprotective in neuronal culVOLUME 284 • NUMBER 12 • MARCH 20, 2009
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In addition to understanding the
potential mechanisms of PDGF-BBmediated neuroprotection, we also
demonstrate PDGF-BB modulation
of LTD. Both NMDAR and
AMPAR-mediated excitatory postsynaptic currents at CA1 synapses
undergo LTD but they differ in
mechanism (62). The induction of
stimulus-activated LTD at CA1 synapses requires a clathrin-dependent
internalization of AMPARs (62). In
contrast, LTD of the NMDAR component at CA1 synapses is independent of clathrin and instead
requires an intact actin cytoskeleton. The inhibition of NMDA-mediated currents in CA1 pyramidal
neurons by PDGF-BB is also very
long lasting and depends upon an
intact actin cytoskeleton (17, 18),
however, it is not clathrin-dependent but is also blocked by inhibitors
of serine-threonine phosphatases
(17). Therefore it closely resembles
FIGURE 7. PDGF-BB treatment alters NMDA signaling to transcription factors in hippocampal neurons. LTD of NMDA synaptic currents.
For “total” NMDA treatment (A–C), 14 –21-day-old hippocampal cultures were treated for 10 min in warm ECF Although NMDAR receptors can be
with vehicle (⫺) or PDGF-BB (⫹), followed by treatment with vehicle or 100 M NMDA and 1 M glycine. All
internalized via clathrin-mediated
treatments were in the presence of 1 M tetrodotoxin, 40 M 6-cyano-7-nitroquinoxaline-2,3-dione, and 5 M
nifedipine. For “extrasynaptic” NMDA treatment (D–F), cultures were treated for 10 min with vehicle or PDGF- endocytosis (63), the application of
BB. During the last 3 min of the PDGF-BB treatment, 50 M MK-801, 10 M bicuculline, 10 M glycine, and 5 M two peptides that interfere with
nifedipine were included to block synaptic NMDA receptors. After either treatment, cells were washed briefly
endocytosis,
and incubated with vehicle or 100 M NMDA, 10 M glycine for 3 min in the presence of 6-cyano-7-nitroqui- clathrin-mediated
noxaline-2,3-dione and nifedipine. A, after total NMDA treatment, membranes were probed with anti-phos- applied intracellularly via the
pho-ERK, phospho-CREB, and ERK. Blots are representative of five to seven experiments and immunoreactivity patch pipette, did not suppress
was quantified versus control (vehicle, ⫺) (B, C). D, after extrasynaptic NMDA treatment, membranes were
inhibition.
probed with anti-phospho-ERK, ERK, and phospho-CREB. Blots are representative of five to seven experiments PDGF-BB-induced
and immunoreactivity was quantified versus control (vehicle, ⫺) (E, F). Phospho-ERK immunoreactivity was This suggests that acute inhibition
normalized to total ERK (both bands were pooled) and phospho-CREB immunoreactivity was normalized to
of NR2B subunits is not the result
total CREB (not shown).
of a clathrin-dependent internaltures and in vivo (21, 23, 61). In this context, our results provide ization of the NR2B subunit but may either be the result of
a potential mechanism for the neuroprotective properties of functional inhibition of NR2B activity or alternatively it sugPDGF␤ receptor signaling. However, recently published evi- gests that the internalization of NR2B receptors is via a
dence suggest that NR2A- or NR2B-containing NMDA recep- clathrin-independent mechanism. We previously reported
tors can contribute to NMDA-induced excitotoxicity, and that that PDGF-BB had no effect on the amplitude of high frethe neuroprotective effects of NR2A-containing NMDA recep- quency LTP (17), however, here we showed that it enhanced
tors are only observed at submaximal concentrations of NMDA the LTD of the CA1 field EPSPs via an NR2B-dependent
(12). Several recent studies indicate that in cultured neurons mechanism. This result is consistent with the suggestion
NR2B containing receptors are preferentially linked to excito- that increasing the ratio of NR2A/NR2B leads to a shift
toxic pathways, whereas NR2A receptors are actually neuro- toward LTD over LTP (45, 48). Our previous observation of
protective (11, 12). The selective block of neuronal damage by a lack of change in the surface expression of NR1 subunits
NR2B versus exacerbation by NR2A antagonists was shown in implies that NR2A subunits might rapidly replace NR2B subthe MCAO model of stroke in adult animals (11). However, units. This concept would be consistent with a report that
whether or not this relationship holds up for adult animals is NR2A versus NR2B subunit composition of synaptic NMDA
somewhat controversial as it has been reported that NR2A con- receptors can be rapidly altered by the high frequency stimtaining receptors may become sources of excitotoxicity in older ulation induction of LTP (64). The change in this intracellucultures (12). PDGF receptors can signal to ERK directly, there- lar Ca2⫹ signal resulting from a PDGF-BB-induced reducfore the neuroprotective effects of PDGF-BB may involve both tion in NR2B receptors is yet to be determined. Also, the
a direct enhancement of phospho-ERK levels as well as a location (synaptic versus extrasynaptic) of the NMDA recepdecrease in the ability of NR2B receptors to promote ERK tors likely contributes to determination of the direction of
dephosphorylation.
synaptic plasticity (48, 65, 66).
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12.
13.
14.
15.
16.
17.

18.
19.
20.
FIGURE 8. The proposed mechanisms of PDGF␤R inhibition of NMDA
receptors and neuroprotection. PDGF␤ receptor activation inhibits NR2Bcontaining NMDA receptors and selectively removes NR2B subunits from the
cell membrane. However, the relationship between these two observations
remains unclear. The removal of NR2B may cause, or be the result of, PDGF␤
receptor inhibition of NMDA currents. PDGF␤ receptor activation is also neuroprotective. PDGF-BB treatment led to an increase in ERK1/2 phosphorylation and prevented extrasynaptic NMDA receptor inhibition of ERK1/2 and
CREB phosphorylation.

We demonstrate that PDGF␤ receptors colocalize and selectively inhibit and internalize NR2B-containing NMDA receptors, thereby altering the signaling of NMDA receptor populations to CREB and ERK1/2 (Fig. 8). Cell surface receptor
expression may be altered by an increase in receptor internalization (as shown in Fig. 8), a decrease in the insertion of NR2B
to the membrane, or both. Taken together, these results suggest
the selective targeting of NR2B-containing NMDA receptors
by PDGF␤ receptors likely contributes to the neuroprotective
effects of PDGF-BB. PDGF␤ receptor signaling is enhanced following ischemic damage and provides some degree of neuroprotection. Therefore, PDGF likely serves to compensate for
neuronal damage following stroke perhaps by both minimizing
cell damage and by enhancing cell proliferation in animals during development. It remains to be determined if the mechanisms that lead to modulation of excitatory synaptic transmission also provide neuroprotection under ischemic conditions.
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